IAG’s Team is Presenting at ESMO, 19-23 Oct 2018 in Munich, Germany

Slider with alias news slider not found.

IAG’s Team is Presenting at ESMO, 19-23 Oct 2018 in Munich, Germany

With novel #cancer treatments, especially with the development of immune system activating drugs (immune-oncology), we are seeing acute demand for the integration of advanced imaging and specific quantitative biomarkers for the accurate assessment of patient response to treatment and understanding of such complex concepts as #pseudo-progression, tumor #micro-environment and #targeted therapies.

The tumour size assessment in the early phase oncology trials is increasingly relying on the use of use objective quantitative information from the advanced image sequences (DCE, DSC, DWI) in addition to standard criteria such as RECIST or iRECIST, in order to decide if the patient should remain on the treatment. This is one of the hottest topics remains and following our 4 abstracts presented at ASCO, we will be presenting 3 new abstracts at ESMO, in Munich, Germany, 19-23 October 2018.  The work of our team on the use of machine learning and AI in neuro-oncology was also selected as an oral presentation and will be acknowledged in ESMO Highlights Session.

Oral Presentation: Radiological phenotyping of IDH Mutation Status in Gliomas using Dynamic Susceptibility Contrast Perfusion-Weighted MRI. 19 October 2018, 16:00 – 17:30, Hall B3 – Room 20, Abstract No: 375O

Poster Discussion: Can Diffusion Tensor MR Imaging Identify Glioma IDH Mutation Status? Poster display session: Breast cancer – early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours – prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care: 22.10.2018, 12:45 – 13:45, Hall A3 – Poster Area Networking Hub, Presentation Number: 396P, Poster No.: 2638, Sotirios Bisdas, Jialin Yuan, Laura Mancini, Diana Roettger Download Poster 

Poster Discussion: Understanding Biological Activity, Tumor Response and Pseudoprogression in a Phase-2b Study of MDNA55 in Adults with Recurrent or Progressive Glioblastoma (GB), Poster display session: CNS tumours: 20.10.2018, 12:45 – 13:45, Hall B3, Room 23, 17:10, Presentation Number: 380PD, Martin Bexon, Achal Singh Achrol, Manish Aghi, Krystof Bankiewicz, Sotirios Bisdas, Andrew Brenner, Nicholas Butowski, Santosh Kesari, Fahar Merchant, Rosemina Merchant, Dina Randazzo, Diana Roettger, Michael Vogelbaum, Miroslaw Zabek and John Sampson Dowload Poster


About IAG

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ESMO 

ESMO is the leading European professional organisation for medical oncology. Comprising 18,000 oncology professionals from over 150 countries, we are the society of reference for oncology education and information. The meeting is a multi-professional platform for oncology education and exchange, and for immense international visibility for scientific research, this year the Congress also features a dedicated nursing track through a collaboration with the European Oncology Nursing Society (EONS).